mRNA-1273.617.2 / Moderna - LARVOL DELTA

Profiling antibody epitopes induced by mRNA-1273 vaccination and boosters. (PubMed, Front Immunol) - "Notably, the strength of antibody responses after booster vaccination differed by the exact vaccine formulation, with variant-updated mRNA-1273.211 and mRNA-1273.617.2 booster formulations inducing significantly stronger S-specific signals than a mRNA-1273 booster. Overall, these results identify key S-specific epitopes targeted by antibodies induced by mRNA-1273 primary and variant-updated booster vaccination."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial) (clinicaltrials.gov) - P2 | N=1270 | Completed | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Phase classification: P1/2 ➔ P2

Phase classification • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial) (clinicaltrials.gov) - P1/2 | N=1270 | Completed | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Active, not recruiting ➔ Completed | Trial completion date: Oct 2024 ➔ Nov 2023 | Trial primary completion date: Oct 2024 ➔ Nov 2023

Trial completion • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants (clinicaltrials.gov) - P2/3 | N=5404 | Completed | Sponsor: ModernaTX, Inc. | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial) (clinicaltrials.gov) - P1/2 | N=1270 | Active, not recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Trial completion date: Mar 2026 ➔ Oct 2024 | Trial primary completion date: Mar 2026 ➔ Oct 2024

Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants (clinicaltrials.gov) - P2/3 | N=5404 | Active, not recruiting | Sponsor: ModernaTX, Inc. | Trial completion date: Apr 2023 ➔ Nov 2023 | Trial primary completion date: Apr 2023 ➔ Nov 2023

Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial) (clinicaltrials.gov) - P1/2 | N=1270 | Active, not recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting ➔ Active, not recruiting

Enrollment closed • Immunology • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial) (clinicaltrials.gov) - P1/2 | N=1500 | Recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Active, not recruiting ➔ Recruiting | N=1068 ➔ 1500

Enrollment change • Enrollment open • Immunology • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial) (clinicaltrials.gov) - P1/2 | N=1068 | Active, not recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting ➔ Active, not recruiting

Enrollment closed • Immunology • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants (clinicaltrials.gov) - P2/3 | N=4658 | Active, not recruiting | Sponsor: ModernaTX, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases